TheStreet cut shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) from a buy rating to a hold rating in a report released on Tuesday.

JAZZ has been the topic of several other reports. Leerink Swann set a $178.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a buy rating in a research note on Friday, October 28th. BMO Capital Markets reaffirmed an outperform rating and issued a $195.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Friday, October 7th. Goldman Sachs Group Inc. reaffirmed a buy rating and issued a $187.00 price target (down from $195.00) on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, September 27th. Mizuho reaffirmed a buy rating and issued a $185.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, September 15th. Finally, Janney Montgomery Scott initiated coverage on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 25th. They issued a neutral rating for the company. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $178.25.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 114.31 on Tuesday. The firm has a market cap of $6.92 billion, a PE ratio of 20.10 and a beta of 1.35. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $160.00. The firm’s 50 day moving average price is $118.10 and its 200-day moving average price is $135.73.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.61 by $0.04. Jazz Pharmaceuticals PLC had a net margin of 24.81% and a return on equity of 30.89%. The firm had revenue of $374 million for the quarter, compared to analyst estimates of $389.34 million. During the same period last year, the firm earned $2.52 earnings per share. Jazz Pharmaceuticals PLC’s revenue for the quarter was up 9.8% compared to the same quarter last year. On average, analysts forecast that Jazz Pharmaceuticals PLC will post $10.05 EPS for the current year.

In other Jazz Pharmaceuticals PLC news, Director Rick E. Winningham sold 633 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $136.45, for a total value of $86,372.85. Following the transaction, the director now directly owns 15,391 shares of the company’s stock, valued at $2,100,101.95. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $126.17, for a total transaction of $25,234.00. Following the completion of the transaction, the senior vice president now directly owns 17,325 shares in the company, valued at $2,185,895.25. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the stock. Cadian Capital Management LP boosted its position in shares of Jazz Pharmaceuticals PLC by 71.6% in the third quarter. Cadian Capital Management LP now owns 1,311,292 shares of the specialty pharmaceutical company’s stock worth $159,296,000 after buying an additional 547,056 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Jazz Pharmaceuticals PLC by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 1,233,053 shares of the specialty pharmaceutical company’s stock worth $174,242,000 after buying an additional 49,967 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of Jazz Pharmaceuticals PLC by 4.8% in the third quarter. BlackRock Fund Advisors now owns 1,047,135 shares of the specialty pharmaceutical company’s stock worth $127,206,000 after buying an additional 47,834 shares during the last quarter. Prudential Financial Inc. boosted its position in shares of Jazz Pharmaceuticals PLC by 2.0% in the second quarter. Prudential Financial Inc. now owns 620,397 shares of the specialty pharmaceutical company’s stock worth $87,668,000 after buying an additional 12,320 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Jazz Pharmaceuticals PLC by 17.2% in the third quarter. Wells Fargo & Company MN now owns 506,079 shares of the specialty pharmaceutical company’s stock worth $61,478,000 after buying an additional 74,342 shares during the last quarter. 88.35% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.